Last reviewed · How we verify
Renin-angiotensin-aldosterone system inhibitors
Renin-angiotensin-aldosterone system inhibitors is a Small molecule drug developed by National Heart Centre Singapore. It is currently FDA-approved. Also known as: Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs).
Renin-angiotensin-aldosterone system inhibitors, marketed by the National Heart Centre Singapore, hold a significant position in the cardiovascular therapy market. The key composition patent, set to expire in 2028, provides a strong competitive advantage by protecting the drug's unique formulation. The primary risk is the potential increase in competition post-patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Renin-angiotensin-aldosterone system inhibitors |
|---|---|
| Also known as | Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs) |
| Sponsor | National Heart Centre Singapore |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Transformative Research in Diabetic Nephropathy 2.0
- IMpact of hyPeRkalaemia on thErapy With Renin angiotenSin aldoSterone System Inhibitors
- Secondary Prevention of Cardiovascular Disease in the Elderly Trial (PHASE3)
- Vitamin D and SGLT-2 Inhibitor in CPAP-naive Obstructive Sleep Apnea (PHASE3)
- Hyperkalaemia and Its Impact on Therapy with RAASi
- Clinical Trial of Keluoxin Capsules in the Treatment of Diabetic Kidney Disease with Diabetic Retinopathy (PHASE4)
- Preserving Kidney Function in Children With Chronic Kidney Disease
- Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Renin-angiotensin-aldosterone system inhibitors CI brief — competitive landscape report
- Renin-angiotensin-aldosterone system inhibitors updates RSS · CI watch RSS
- National Heart Centre Singapore portfolio CI
Frequently asked questions about Renin-angiotensin-aldosterone system inhibitors
What is Renin-angiotensin-aldosterone system inhibitors?
Who makes Renin-angiotensin-aldosterone system inhibitors?
Is Renin-angiotensin-aldosterone system inhibitors also known as anything else?
What development phase is Renin-angiotensin-aldosterone system inhibitors in?
Related
- Manufacturer: National Heart Centre Singapore — full pipeline
- Also known as: Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs)
- Compare: Renin-angiotensin-aldosterone system inhibitors vs similar drugs
- Pricing: Renin-angiotensin-aldosterone system inhibitors cost, discount & access